Vδ2 T-cell engagers bivalent for Vδ2-TCR binding provide anti-tumor immunity and support robust Vγ9Vδ2 T-cell expansion
By enhancing the number of Vγ9Vδ2 T-cells available to exert antitumor effector functions, these novel Vδ2-bivalent bispecific T cell engagers may promote the overall efficacy of bispecific Vγ9Vδ2 T-cell engagement, particularly in patients with relatively low levels of Vγ9Vδ2 T-cells.
Authors
- Milon de Jong
- Victoria Iglesias‐Guimarais (ORCID: https://orcid.org/0009-0009-4116-884X)
- D. Lutje Hulsik (ORCID: https://orcid.org/0000-0001-8074-8147)
- Hans van Vliet (ORCID: https://orcid.org/0000-0001-7846-8613)
- Myrthe Veth (ORCID: https://orcid.org/0009-0006-3551-2243)
- Tanja D. de Gruijl (ORCID: https://orcid.org/0000-0003-1464-8978)
- Pauline M. van Helden (ORCID: https://orcid.org/0009-0003-8241-5145)
- Lisa A. King (ORCID: https://orcid.org/0009-0001-8705-150X)
- Parsa Yousefi
Institutions
- Lava Therapeutics (Netherlands) (NL)
- Amsterdam University Medical Centers (NL)
- Cancer Center Amsterdam (NL)
- Vrije Universiteit Amsterdam (NL)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-10-18
- DOI
- https://doi.org/10.3389/fonc.2024.1474007
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.57